Study shows record surge in reduced kidney function worldwide +++

https://www.news-medical.net/news/20251108/Study-shows-record-surge-in-reduced-kidney-function-worldwide.aspx Record numbers of men and women globally are now estimated to have reduced kidney function, a new study shows. Figures rose from 378 million people with the disease in 1990 to 788 million in 2023 as the world population grew and aged, making it for the first time a top 10 cause of death worldwide. Preclinical evidence supports sotagliflozin's superior efficacy in attenuating salt-induced kidney damage https://www.news-medical.net/news/20251108/Preclinical-evidence-supports-sotagliflozins-superior-efficacy-in-attenuating-salt-induced-kidney-damage.aspx Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed to treat type 2 diabetes, have significant heart- and kidney- protective effects. In the kidney, SGLT2 reabsorbs approximately 97% offiltered glucose in the S1 and S2 segments of the proximal tubule, while SGLT1reabsorbs the remainder in the S3 segment. Using estimated risks and preferences to justify intensive BP control in CKD patients https://www.news-medical.net/news/20251108/Using-estimated-risks-and-preferences-to-justify-intensive-BP-control-in-CKD-patients.aspx An analysis of the Systolic Blood Pressure Intervention Trial (SPRINT) indicates that nearly all adults with chronic kidney disease (CKD) would have benefits that outweigh the harm from a systolic blood pressure target of <120 mm Hg compared with a target of <140 mm Hg. Thefindings will be presented at ASN Kidney Week 2025 November 5– 9.